Entrada Therapeutics, Inc. (NASDAQ:TRDA) CFO Sells $172,567.26 in Stock

Entrada Therapeutics, Inc. (NASDAQ:TRDA) CFO Kory James Wentworth sold 8,637 shares of Entrada Therapeutics stock in a transaction on Monday, November 11th. The stock was sold at an average price of $19.98, for a total transaction of $172,567.26. Following the transaction, the chief financial officer now owns 73,849 shares in the company, valued at approximately $1,475,503.02. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink.

Kory James Wentworth also recently made the following trade(s):

• On Monday, September 9th, Kory James Wentworth sold 3,195 shares of Entrada Therapeutics stock. The shares were sold at an average price of $14.97, for a total value of $47,829.15.

Entrada Therapeutics Stock Up 0.9 %

Shares of NASDAQ TRDA opened at $19.96 on Thursday. Entrada Therapeutics, Inc. has a 12-month low of $10.75 and a 12-month high of $20.49. The firm has a market cap of $746.90 million, a PE ratio of 12.55 and a beta of -0.26. The company’s fifty day simple moving average is $16.62 and its 200 day simple moving average is $15.85.

Entrada Therapeutics (NASDAQ:TRDA) last issued its earnings results on Tuesday, August 13th. The company reported $1.55 EPS for the quarter, beating analysts’ consensus estimates of $0.65 by $0.90. Entrada Therapeutics had a return on equity of 16.11% and a net margin of 25.53%. The business had revenue of $94.69 million during the quarter, compared to analyst estimates of $55.00 million. On average, equities analysts predict that Entrada Therapeutics, Inc. will post 1.07 earnings per share for the current year.

Analysts Set New Price Targets

A number of analysts have weighed in on the stock. HC Wainwright increased their target price on shares of Entrada Therapeutics from $18.00 to $20.00 and gave the company a “buy” rating in a research report on Wednesday, November 6th. Oppenheimer boosted their target price on shares of Entrada Therapeutics from $25.00 to $28.00 and gave the company an “outperform” rating in a report on Wednesday, November 6th.

Hedge Funds Weigh In On Entrada Therapeutics

Large investors have recently modified their holdings of the company. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its stake in shares of Entrada Therapeutics by 34.7% in the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 14,156 shares of the company’s stock valued at $226,000 after buying an additional 3,644 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its position in Entrada Therapeutics by 14.6% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 185,984 shares of the company’s stock valued at $2,972,000 after acquiring an additional 23,643 shares in the last quarter. Massachusetts Financial Services Co. MA bought a new stake in Entrada Therapeutics during the 3rd quarter worth approximately $1,109,000. Connor Clark & Lunn Investment Management Ltd. increased its holdings in Entrada Therapeutics by 132.4% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 138,605 shares of the company’s stock worth $2,215,000 after purchasing an additional 78,953 shares in the last quarter. Finally, GSA Capital Partners LLP lifted its holdings in shares of Entrada Therapeutics by 71.8% in the third quarter. GSA Capital Partners LLP now owns 36,577 shares of the company’s stock valued at $585,000 after purchasing an additional 15,284 shares in the last quarter. 86.39% of the stock is currently owned by institutional investors.

About Entrada Therapeutics

Entrada Therapeutics, Inc, a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1.